3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
427
Neoplasms, Plasma Cell
68
Lymphoma, Mantle-Cell
66
Lymphoma
65
Recurrence
64
Lymphoma, Non-Hodgkin
43
Lymphoma, Follicular
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Leukemia, Myeloid, Acute
36
Lymphoma, Large B-Cell, Diffuse
34
Waldenstrom Macroglobulinemia
33
Lymphoma, B-Cell, Marginal Zone
30
Leukemia, Lymphocytic, Chronic, B-Cell
28
Neoplasms
24
Carcinoma, Non-Small-Cell Lung
24
Immunoglobulin Light-chain Amyloidosis
23
Leukemia
21
Hodgkin Disease
17
Lymphoma, B-Cell
14
Burkitt Lymphoma
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Myelodysplastic Syndromes
13
Lymphoma, Large-Cell, Anaplastic
13
Hematologic Neoplasms
13
Immunoblastic Lymphadenopathy
12
Breast Neoplasms
12
Mycosis Fungoides
11
Lymphoma, T-Cell, Cutaneous
11
Lymphoma, Large-Cell, Immunoblastic
11
Congenital Abnormalities
11
Interventions
enzalutamide
6
Abiraterone Acetate
6
olaparib
5
Docetaxel
5
darolutamide
4
Prednisone
4
Pluvicto
4
cabazitaxel
3
testosterone 17 beta-cypionate
2
radium Ra 223 dichloride
2
fludarabine
2
abiraterone
2
Prednisolone
2
Nivolumab
2
Cyclophosphamide
2
Androgen Antagonists
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
lactitol
1
fludarabine phosphate
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
alovudine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Castration-resistant Prostate Cancer
×
Bortezomib
×
Clear all
NCT06029998
2025-11-28
BORXPTEN
University of Utah
Phase 2
Recruiting
22 enrolled